MARK2 and colorectal cancer: Meanwhile, pathway enrichment of positive controls vemurafenib and sorafenib identified four additional protein targets involved in KEGG colorectal cancer: A-Raf proto-oncogene, serine/threonine kinase (A-Raf), Raf-1 proto-oncogene, serine/threonine kinase (Raf-1), mitogen-activated protein kinase kinase 2 (MAP2K2), and transforming growth factor beta receptor 2 (TGFBR2) (Supplementary Table S3).